Arecor Therapeutics Full Year 2024 Earnings: Misses Expectations
Revenue: UK£5.05m (up 11% from FY 2023).
Net loss: UK£10.2m (loss widened by 20% from FY 2023).
UK£0.31 loss per share (further deteriorated from UK£0.28 loss in FY 2023).
We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Revenue missed analyst estimates by 7.6%. Earnings per share (EPS) also missed analyst estimates by 3.3%.
Looking ahead, revenue is forecast to stay flat during the next 2 years compared to a 14% growth forecast for the Biotechs industry in the United Kingdom.
Performance of the British Biotechs industry.
The company's share price is broadly unchanged from a week ago.
We should say that we've discovered 5 warning signs for Arecor Therapeutics (1 shouldn't be ignored!) that you should be aware of before investing here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
Reeves to promise investment in ‘renewal' as she unveils spending plans
Rachel Reeves will vow to 'invest in Britain's renewal' as she reveals her spending plans for the coming years on Wednesday. The Chancellor is expected to announce big increases in spending on the NHS, defence and schools as part of a spending review set to include £113 billion of investment thanks to looser borrowing rules. She will also reveal changes to the Treasury's 'green book' rules that govern which projects receive investment in an effort to boost spending outside London and the South East. Arguing that this investment is 'possible only because of the stability I have introduced' after the October budget, Ms Reeves is expected to say her spending review will 'ensure that renewal is felt in people's everyday lives, their jobs, their communities'. She will say: 'The priorities in this spending review are the priorities of working people. 'To invest in our country's security, health and economy so working people all over our country are better off.' Among the other announcements expected at the spending review is £39 billion for affordable homes over the next 10 years as the Government seeks to meet its promise of building 1.5 million homes by the next election. The Treasury said this would see annual investment in affordable housing rise to £4 billion by 2029/30, almost double the average of £2.3 billion between 2021 and 2026. A Government source said: 'We're turning the tide against the unacceptable housing crisis in this country with the biggest boost to social and affordable housing investment in a generation, delivering on our plan for change commitment to get Britain building.' The Chancellor has also already announced some £15.6 billion of spending on public transport in England's city regions, and £16.7 billion for nuclear power projects, the bulk of which will fund the new Sizewell C plant in Suffolk. But the spending review is expected to set out tough spending limits for departments other than health, defence and education. Although Ms Reeves is reported to have agreed to an above-inflation increase in the policing budget, this is thought to have come at the expense of cuts in other parts of Home Office spending. And sources close to London Mayor Sir Sadiq Khan have expressed concern that the spending review will have nothing for the capital. Ahead of the spending review, the Institute for Fiscal Studies has warned that any increase in NHS funding above 2.5% is likely to mean real-terms cuts for other departments or further tax rises to come in the budget this autumn. The Chancellor has already insisted that her fiscal rules remain in place, along with Labour's manifesto commitment not to increase income tax, national insurance or VAT. She will say on Wednesday: 'I have made my choices. In place of chaos, I choose stability. In place of decline, I choose investment. In place of retreat, I choose national renewal. 'These are my choices. These are this Government's choices. These are the British people's choices.'
Yahoo
an hour ago
- Yahoo
Abercrombie & Fitch First Quarter 2026 Earnings: Beats Expectations
Revenue: US$1.10b (up 7.5% from 1Q 2025). Net income: US$80.4m (down 29% from 1Q 2025). Profit margin: 7.3% (down from 11% in 1Q 2025). The decrease in margin was driven by higher expenses. EPS: US$1.63 (down from US$2.24 in 1Q 2025). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue exceeded analyst estimates by 3.5%. Earnings per share (EPS) also surpassed analyst estimates by 20%. Looking ahead, revenue is forecast to grow 3.1% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Specialty Retail industry in the US. Performance of the American Specialty Retail industry. The company's shares are up 4.6% from a week ago. Before you take the next step you should know about the 1 warning sign for Abercrombie & Fitch that we have uncovered. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
lululemon athletica First Quarter 2026 Earnings: In Line With Expectations
Revenue: US$2.37b (up 7.3% from 1Q 2025). Net income: US$314.6m (down 2.1% from 1Q 2025). Profit margin: 13% (down from 15% in 1Q 2025). The decrease in margin was driven by higher expenses. EPS: US$2.61. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue was in line with analyst estimates. Earnings per share (EPS) was also in line with analyst expectations. Looking ahead, revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Luxury industry in the US. Performance of the American Luxury industry. The company's shares are down 20% from a week ago. Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We have a graphic representation of lululemon athletica's balance sheet and an in-depth analysis of the company's financial position. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
